Ibrutinib 140mg is a targeted therapy capsule that inhibits Bruton's tyrosine kinase (BTK), disrupting signaling in malignant B-cells to halt their uncontrolled growth. Primarily prescribed for blood cancers like mantle cell lymphoma after prior treatments and chronic lymphocytic leukemia, it offers a once-daily oral option often used until disease progression. Available as Imbruvica, this formulation supports precise administration in specific hepatic impairment cases or combination regimens, enhancing patient convenience in oncology care.
​